Grady Chang

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised Tetra Tech, a leading global provider of consulting and engineering services that focuses on water, environment, sustainable infrastructure, renewable energy and international development, on its Rule 144A offering of $575 million aggregate principal amount of 2.25% convertible senior notes due 2028, which includes the full exercise of the initial purchasers’ option to purchase an additional $75 million aggregate principal amount of notes. Partners John-Paul Motley, Mischi a Marca, Jason Savich, Ellie Guadiana and Logan Tiari led the Cooley team advising Tetra Tech.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised the underwriters in Vivid Seats’ $128 million follow-on offering. Vivid Seats is an online ticket marketplace connecting fans to live events and artists. As the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theaters and comedy, Vivid Seats operates in two segments – marketplace and resale. Lawyers Christina Roupas, Courtney Tygesson, Grady Chang, Sam Paullin, Leah Duncan and Adam Bloom led the Cooley team.

Cooley advised Geron Corporation, a late-stage biopharmaceutical company in California pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies, on its $227.8 million follow-on offering. Partners Chadwick Mills and Kristin VanderPas led the Cooley team.